Enveric Biosciences Reports Results From Animal Studies Demonstrating Oral Bioavailability And Well Tolerated Side Effect Profile For EB-373
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has reported results from animal studies showing oral bioavailability and a well-tolerated side effect profile for EB-373. The results could potentially lead to further development and testing of the drug.
July 17, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive results from Enveric Biosciences' animal studies for EB-373 could potentially boost the company's stock in the short term.
The positive results from the animal studies for EB-373 indicate that the drug is well-tolerated and has oral bioavailability. This could potentially lead to further development and testing of the drug, which could in turn boost investor confidence and the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100